NavDx® testing can detect molecular residual disease present after treatment, enabling timely intervention to limit progression and minimize treatment morbidity.
Naveris is now CareDx. Advancing viral-mediated cancer care through precision medicine diagnostics. Read More
NavDx® testing can detect molecular residual disease present after treatment, enabling timely intervention to limit progression and minimize treatment morbidity.
(833)-NAVERIS / (833)-628-3747
support@naveris.com
Investor Relations
ir@naveris.com